- Home
- VRAR vs FEMY Comparison
VRAR vs FEMY Comparison
Compare VRAR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- FEMY
- Stock Information
- Founded
- VRAR 2016
- FEMY 2004
- Country
- VRAR United States
- FEMY United States
- Employees
- VRAR N/A
- FEMY N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- FEMY Medical/Dental Instruments
- Sector
- VRAR Technology
- FEMY Health Care
- Exchange
- VRAR Nasdaq
- FEMY Nasdaq
- Market Cap
- VRAR 33.3M
- FEMY 28.3M
- IPO Year
- VRAR 2021
- FEMY 2021
- Fundamental
- Price
- VRAR $1.59
- FEMY $0.80
- Analyst Decision
- VRAR Strong Buy
- FEMY Strong Buy
- Analyst Count
- VRAR 1
- FEMY 3
- Target Price
- VRAR $2.62
- FEMY $8.67
- AVG Volume (30 Days)
- VRAR 190.6K
- FEMY 342.7K
- Earning Date
- VRAR 05-15-2025
- FEMY 05-08-2025
- Dividend Yield
- VRAR N/A
- FEMY N/A
- EPS Growth
- VRAR N/A
- FEMY N/A
- EPS
- VRAR N/A
- FEMY N/A
- Revenue
- VRAR $8,756,789.00
- FEMY $1,699,232.00
- Revenue This Year
- VRAR $6.59
- FEMY $526.11
- Revenue Next Year
- VRAR $30.43
- FEMY $83.00
- P/E Ratio
- VRAR N/A
- FEMY N/A
- Revenue Growth
- VRAR N/A
- FEMY 61.97
- 52 Week Low
- VRAR $0.50
- FEMY $0.69
- 52 Week High
- VRAR $7.00
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- VRAR 61.35
- FEMY 25.45
- Support Level
- VRAR $1.45
- FEMY $0.69
- Resistance Level
- VRAR $1.76
- FEMY $0.83
- Average True Range (ATR)
- VRAR 0.14
- FEMY 0.06
- MACD
- VRAR 0.01
- FEMY -0.02
- Stochastic Oscillator
- VRAR 66.67
- FEMY 26.95
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.